MissionIR Articles

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, announced that a Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected…

NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The…

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, said its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa, citing the…

NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds through the sale of 1,333,334 common…

NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of measles, providing potential incentives including tax credits, fee exemptions…

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, “Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites,” has been accepted for presentation at the…